Mouse models of anemia of cancer

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Kim, Airie ^a   Rivera, Seth ^a   Shprung, Dana ^a   Limbrick, Donald ^a   Gabayan, Victoria ^a   Nemeth, Elizabeta ^a   Ganz, Tomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEPCIDIN; IRON; MESSENGER RNA;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; BRUCELLA ABORTUS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ERYTHROPOIESIS; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOPERITONEUM; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON RESTRICTION; LUNG METASTASIS; MALE; MELANOMA METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; RETICULOCYTOSIS; ANEMIA, IRON-DEFICIENCY; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; GENETICS; INFLAMMATION; METABOLISM; NEOPLASM; PATHOLOGY; QUALITY OF LIFE;

ANEMIA, IRON-DEFICIENCY; ANIMALS; BRUCELLA ABORTUS; DISEASE MODELS, ANIMAL; FEMALE; HEPCIDINS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS; QUALITY OF LIFE; RNA, MESSENGER;

EID: 84899802247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093283     Document Type: Article

References (39)

1. Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116 Suppl 7A: 11S-26S.
2. Kosmidis P, Krzakowski M, Investigators E (2005) Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)? Lung Cancer 50: 401-412.
3. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, et al. (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95: 888-895. (Pubitemid 34839682)
4. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S (2003) Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 98: 1786-1801. (Pubitemid 37310220)
5. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91: 2214-2221. (Pubitemid 32552805)
6. Dicato M, Plawny L, Diederich M (2010) Anemia in cancer. Ann Oncol 21 Suppl 7: vii167-172.
7. Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, et al. (2008) Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 14: 3262-3267.
8. Adamson JW (2008) The anemia of inflammation/malignancy: mechanisms and management. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program: 159-165.
9. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352: 1011-1023.
10. Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276: 7806-7810.
11. Ganz T, Nemeth E (2012) Hepcidin and iron homeostasis. Biochim Biophys Acta 1823: 1434-1443.
12. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093. (Pubitemid 40007660)
13. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, et al. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J ClinInvest 113: 1271-1276. (Pubitemid 39069926)
14. Wrighting DM, Andrews NC (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108: 3204-3209.
15. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, et al. (2007) STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 132: 294-300. (Pubitemid 46108739)
16. Verga Falzacappa MV, Vujic SM, Kessler R, Stolte J, Hentze MW, et al. (2007) STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109: 353-358. (Pubitemid 46053077)
17. Songur N, Kuru B, Kalkan F, Ozdilekcan C, Cakmak H, et al. (2004) Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 90: 196-200. (Pubitemid 38745608)
18. Zakrzewska I, Poznanski J (2001) [Changes of serum il-6 and CRP after chemotherapy in patients with ovarian carcinoma]. Pol Merkur Lekarski 11: 210-213.
19. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, et al. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113: 1271-1276. (Pubitemid 39069926)
20. Ramos E, Kautz L, Rodriguez R, Hansen M, Gabayan V, et al. (2011) Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology 53: 1333-1341.
21. Zhang Z, Zhang F, Guo X, An P, Tao Y, et al. (2012) Ferroportin1 in hepatocytes and macrophages is required for the efficient mobilization of body iron stores in mice. Hepatology 56: 961-971.
22. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, et al. (2000) Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21: 585-591. (Pubitemid 30214011)
23. Lesbordes-Brion JC, Viatte L, Bennoun M, Lou DQ, Ramey G, et al. (2006) Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood 108: 1402-1405. (Pubitemid 44232044)
24. Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, et al. (2012) Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 120: 3829-3836.
25. Goodnough JB, Ramos E, Nemeth E, Ganz T (2012) Inhibition of hepcidin transcription by growth factors. Hepatology 56: 291-299.
26. Wong SS, Qutishat AS, Lange J, Gornet TG, Buja LM (1996) Detection of iron-deficiency anemia in hospitalized patients by zinc protoporphyrin. Clin Chim Acta 244: 91-101. (Pubitemid 26050202)
27. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, et al. (2004) IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 314: 363-369. (Pubitemid 38084725)
28. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S (2006) Suppression of hepcidin during anemia requires erythropoietic activity. Blood 108: 3730-3735. (Pubitemid 44864551)
29. Lynch EC (1990) Peripheral Blood Smear. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston.
30. Demetri GD (2001) Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 84 Suppl 1: 31-37.
31. Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412-3425. (Pubitemid 28481641)
32. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, et al. (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40: 2293-2306. (Pubitemid 39348881)
33. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, et al. (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218-1234. (Pubitemid 27106310)
34. Aapro M, Spivak JL (2009) Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist 14 Suppl 1: 6-15.
35. Spivak JL, Gascon P, Ludwig H (2009) Anemia management in oncology and hematology. Oncologist 14 Suppl 1: 43-56.
36. Butterfield AM, Luan P, Witcher DR, Manetta J, Murphy AT, et al. (2010) A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin Chem 56: 1725-1732.
37. Ukarma L, Johannes H, Beyer U, Zaug M, Osterwalder B, et al. (2009) Hepcidin as a predictor of response to epoetin therapy in anemic cancer patients. Clin Chem 55: 1354-1360.
38. Sasu BJ, Li H, Rose MJ, Arvedson TL, Doellgast G, et al. (2010) Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI). Blood Cells Mol Dis 45: 238-245.
39. Kim A, Fung E, Parikh SG, Valore EV, Gabayan V, et al. (2014) A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood 123: 1129-1136.